Rationally Designed High-affinity 2-amino-6-halopurine Heat Shock Protein 90 Inhibitors That Exhibit Potent Antitumor Activity.
From: Department of Chemistry, Biogen Idec, Inc., 5200 Research Place, San Diego, CA 92122, USA. srinivasrao.kasibhatla@biogenidec.com
Journal of medicinal chemistry
- Publish Date: Jun 2007
- ISSN: 0022-2623
- Volume: 50
- Issue: 12
- Pages: 2767-78
- Medium: Print
- Language: English
- Citation (JAMA): Kasibhatla Srinivas R, Hong Kevin, Biamonte Marco A, et al. Rationally Designed High-affinity 2-amino-6-halopurine Heat Shock Protein 90 Inhibitors That Exhibit Potent Antitumor Activity.. J. Med. Chem. Jun 2007;50:2767-78
Abstract
Heat shock protein 90 (Hsp90) is a molecular chaperone protein implicated in stabilizing the conformation and maintaining the function of many cell-signaling proteins. Many oncogenic proteins are more dependent on Hsp90 in maintaining their conformation, stability, and maturation than their normal counterparts. Furthermore, recent data show that Hsp90 exists in an activated form in malignant cells but in a latent inactive form in normal tissues, suggesting that inhibitors selective for the activated form could provide a high therapeutic index. Hence, Hsp90 is emerging as an exciting new target for the treatment of cancer. We now report on a novel series of 2-amino-6-halopurine Hsp90 inhibitors exemplified by 2-amino-6-chloro-9-(4-iodo-3,5-dimethylpyridin-2-ylmethyl)purine (30). These highly potent inhibitors (IC50 of 30 = 0.009 microM in a HER-2 degradation assay) also display excellent antiproliferative activity against various tumor cell lines (IC50 of 30 = 0.03 microM in MCF7 cells). Moreover, this class of inhibitors shows higher affinity for the activated form of Hsp90 compared to our earlier 8-sulfanylpurine Hsp90 inhibitor series. When administered orally to mice, these compounds exhibited potent tumor growth inhibition (>80%) in an N87 xenograft model, similar to that observed with 17-allylamino-17-desmethoxygeldanamycin (17-AAG), which is a compound currently in phase I/II clinical trials.
Mesh Headings (Keywords): Adenine, Administration, Oral, Animals, Antineoplastic Agents, Biological Availability, Cell Line, Tumor, Drug Design, Drug Screening Assays, Antitumor, Female, HSP90 Heat-Shock Proteins, Humans, Mice, Mice, Inbred BALB C, Mice, Nude, Neoplasm Transplantation, Purines, Pyridines, Receptor, erbB-2, Structure-Activity Relationship, Transplantation, Heterologous
Check for Full Text / PubMed Unique Identifier (PMID): 17488003
This abstract is part of PubMed, a service of the U.S. National Library of Medicine. PubMed includes more than 17 million citations from MEDLINE and other life science journals for biomedical articles. See Copyright and Disclaimers.
Linked medical terms appearing on this page are added by Healia to help readers find more information and are not part of the original PubMed document.
The data herein was last updated on July 8th, 2008 and may not reflect the most current and accurate data available from NLM.